摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[(chlorocarbonyl)oxy]methyl 2-methylpropanoate | 353736-67-1

中文名称
——
中文别名
——
英文名称
[(chlorocarbonyl)oxy]methyl 2-methylpropanoate
英文别名
carbonochloridoyloxymethyl 2-methylpropanoate
[(chlorocarbonyl)oxy]methyl 2-methylpropanoate化学式
CAS
353736-67-1
化学式
C6H9ClO4
mdl
——
分子量
180.588
InChiKey
JOWSLMCIDSDGEG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    192.5±23.0 °C(Predicted)
  • 密度:
    1.234±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    11
  • 可旋转键数:
    5
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    52.6
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES<br/>[FR] BIOPRECURSEURS ACYLOXYMETHYLCARBAMATE DES OXAZOLIDINONES
    申请人:UPJOHN CO
    公开号:WO2005028473A1
    公开(公告)日:2005-03-31
    The present invention relates to acyloxymethylcarbamate oxazolidinones. The compounds of the present invention have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria.
    本发明涉及酰氧甲基氨基甲酸噁唑烷酮。本发明的化合物具有优良的口服生物利用度,对革兰氏阳性和阴性细菌具有强效活性。
  • 9-Aminocarbonylsubstituted derivatives of glycylcyclines
    申请人:Sum Phaik-Eng
    公开号:US20070049564A1
    公开(公告)日:2007-03-01
    This invention provides compounds of Formula I having the structure where R 1 , R 2 , R 3 and A are defined in the specification or a pharmaceutically acceptable salt thereof useful as antibacterial agents. Compounds according to Formula (II): where Q, R 4 , R 5 , R 6 and R 10 and A are defined in the specification are useful as chemical intermediates.
    这项发明提供了具有结构的化合物,其中R1、R2、R3和A在规范中定义,或其药用盐,可用作抗菌剂。根据公式(II)的化合物: 其中Q、R4、R5、R6和R10以及A在规范中定义,可用作化学中间体。
  • Acyloxymethylcarbamate prodrugs of oxazolidinones
    申请人:Josyula Venkata Nagendra Vara Prasad
    公开号:US20050267104A1
    公开(公告)日:2005-12-01
    The present invention relates to acyloxymethylcarbamate oxazolidinones. The compounds of the present invention have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria.
    本发明涉及酰氧甲基氨基甲酸噁唑烷酮。本发明的化合物具有强大的活性和良好的口服生物利用度,对革兰氏阳性和革兰氏阴性细菌具有优异的抗菌活性。
  • Enhanced propertied pesticides
    申请人:Rohm and Haas Company
    公开号:US06376548B1
    公开(公告)日:2002-04-23
    This invention relates to enhanced propertied pesticides which can be used as fungicides, herbicides, insecticides, rodenticides or biocides, compositions comprising enhanced propertied pesticides, and the method of use of enhanced propertied pesticides and their compositions. It has been found that certain pesticidal compounds can be substituted with a moiety which comprises a substituent which enhances or changes the properties of the pesticidal compound. Additionally, some of the compounds of this invention may comprise two pesticidal components which can be different from one another. The invention relates also to pesticidal compositions comprising a pesticidal compound of this invention and an pesticidally acceptable carrier as well as methods of controlling a pest comprising applying a pesticidally effective amount of a composition comprising a compound of this invention and a pesticidally acceptable carrier to the pest, to the locus of the pest or to the growth medium of said pest.
    本发明涉及增强性能杀虫剂,可用作杀菌剂、除草剂杀虫剂杀鼠剂生物杀剂,以及包含增强性能杀虫剂的组合物和增强性能杀虫剂及其组合物的使用方法。发现某些杀虫化合物可用含有增强或改变杀虫化合物性质的取代基的基团替代。此外,本发明的某些化合物可能包含两种不同的杀虫成分。本发明还涉及包含本发明中的杀虫化合物和杀虫剂可接受的载体的杀虫剂组合物,以及控制害虫的方法,包括将本发明中的化合物和杀虫剂可接受的载体的杀虫剂组合物的有效量施用于害虫、害虫生长地点或害虫的生长介质。
  • Cycloalkyl-Substituted Imidazole Derivative
    申请人:Nagata Tsutomu
    公开号:US20130022587A1
    公开(公告)日:2013-01-24
    A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R 1 , R 2 , and R 3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R 4 represents a hydrogen atom or a prodrug group; and Y represents —CH 2 —CHR 5 —CH 2 —NHR 6 (wherein R 5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R 6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.
    以下是通式(I)所代表的化合物或其药学上可接受的盐,其中A代表一个C3到C12的环烷基,该环烷基可以被一个到三个选自基、羟基、C1到C6烷基等的基团所取代;R1、R2和R3各自独立地代表氢原子、基或C1到C6烷基;R4代表氢原子或前药基团;Y代表—CH2—CHR5— —NHR6(其中R5代表氢原子、C1到C6烷基或C1到C6烷氧基,R6代表氢原子或前药基团)等,具有极好的TAFIa抑制活性,是治疗心肌梗死、心绞痛、急性冠状动脉综合征、脑梗死、深静脉血栓形成、肺栓塞等疾病的治疗药物。
查看更多